Adicet Bio, Inc. Proceeds from Sale and Maturity of Marketable Securities
Adicet Bio, Inc. (ACET) reported Proceeds from Sale and Maturity of Marketable Securities of $2.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2022-03-15
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-12-31 was $12.81M, a 12.86% increase year-over-year.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-09-30 was -$12.52M.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-06-30 was $15.00M, a 40.00% decline year-over-year.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2020-03-31 was $42.50M, a 0.00% change year-over-year.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $2.75M, a 95.24% decline from fiscal 2020.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for fiscal 2020 was $57.79M, a 98.61% increase from fiscal 2019.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for fiscal 2019 was $29.10M, a 287.99% increase from fiscal 2018.
- Adicet Bio, Inc. proceeds from sale and maturity of marketable securities for fiscal 2018 was $7.50M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 9 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $2.75M 10-K · filed 2022-03-15 | |||||
| 2020-12-31 | $12.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $293.00K derived: sum of 2 quarters · filed 2022-03-15 | $15.29M derived: sum of 3 quarters · filed 2022-03-15 | $57.79M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$12.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.48M derived: sum of 2 quarters · filed 2020-11-05 | $44.98M 10-Q · filed 2020-11-05 | $56.33M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2020-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $57.50M 10-Q · filed 2020-07-30 | $68.85M derived: sum of 3 quarters · filed 2021-03-12 | $19.10M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2020-03-31 | $42.50M 10-Q · filed 2020-05-07 | $53.85M derived: sum of 2 quarters · filed 2021-03-12 | $4.10M derived: sum of 3 quarters · filed 2021-03-12 | $29.10M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-12-31 | $11.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$38.40M derived: sum of 2 quarters · filed 2021-03-12 | -$13.40M derived: sum of 3 quarters · filed 2021-03-12 | $29.10M 10-K · filed 2021-03-12 | $141.50M 10-K · filed 2020-03-12 | |
| 2019-09-30 | -$49.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$24.75M derived: sum of 2 quarters · filed 2020-11-05 | $17.75M 10-Q · filed 2020-11-05 | $105.50M 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $67.50M 10-Q · filed 2020-07-30 | ||||
| 2019-03-31 | $42.50M 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | $7.50M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |